187 related articles for article (PubMed ID: 9704488)
1. EBV specific CTL: a model for immune therapy.
Rooney CM; Heslop HE; Brenner MK
Vox Sang; 1998; 74 Suppl 2():497-8. PubMed ID: 9704488
[TBL] [Abstract][Full Text] [Related]
2. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.
O'Reilly RJ; Small TN; Papadopoulos E; Lucas K; Lacerda J; Koulova L
Springer Semin Immunopathol; 1998; 20(3-4):455-91. PubMed ID: 9870257
[No Abstract] [Full Text] [Related]
3. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
Burns DM; Crawford DH
Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
[TBL] [Abstract][Full Text] [Related]
5. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.
Vickers MA; Wilkie GM; Robinson N; Rivera N; Haque T; Crawford DH; Barry J; Fraser N; Turner DM; Robertson V; Dyer P; Flanagan P; Newlands HR; Campbell J; Turner ML
Br J Haematol; 2014 Nov; 167(3):402-10. PubMed ID: 25066775
[TBL] [Abstract][Full Text] [Related]
6. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
Davis JE; Moss DJ
Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
[TBL] [Abstract][Full Text] [Related]
7. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
[TBL] [Abstract][Full Text] [Related]
9. Generation of EBV-specific CTLs suitable for adoptive immunotherapy of EBV-associated lymphoproliferative disease following allogeneic transplantation.
Hoffmann T; Russell C; Vindelov L
APMIS; 2002 Feb; 110(2):148-57. PubMed ID: 12064870
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus, B cell lymphoproliferative disease, and SCID mice: modeling T cell immunotherapy in vivo.
Johannessen I; Bieleski L; Urquhart G; Watson SL; Wingate P; Haque T; Crawford DH
J Med Virol; 2011 Sep; 83(9):1585-96. PubMed ID: 21739450
[TBL] [Abstract][Full Text] [Related]
11. Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants.
O'Reilly RJ; Lacerda JF; Lucas KG; Rosenfield NS; Small TN; Papadopoulos EB
Important Adv Oncol; 1996; ():149-66. PubMed ID: 8791134
[No Abstract] [Full Text] [Related]
12. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
Rooney CM; Smith CA; Ng CY; Loftin S; Li C; Krance RA; Brenner MK; Heslop HE
Lancet; 1995 Jan; 345(8941):9-13. PubMed ID: 7799740
[TBL] [Abstract][Full Text] [Related]
13. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.
Smith CA; Ng CY; Heslop HE; Holladay MS; Richardson S; Turner EV; Loftin SK; Li C; Brenner MK; Rooney CM
J Hematother; 1995 Apr; 4(2):73-9. PubMed ID: 7633844
[TBL] [Abstract][Full Text] [Related]
14. Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
Heslop HE; Rooney CM
Immunol Rev; 1997 Jun; 157():217-22. PubMed ID: 9255632
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.
Heslop HE; Slobod KS; Pule MA; Hale GA; Rousseau A; Smith CA; Bollard CM; Liu H; Wu MF; Rochester RJ; Amrolia PJ; Hurwitz JL; Brenner MK; Rooney CM
Blood; 2010 Feb; 115(5):925-35. PubMed ID: 19880495
[TBL] [Abstract][Full Text] [Related]
16. Preventing Epstein-Barr virus lymphoproliferative disease after bone marrow transplantation.
Heslop HE
J Immunother; 2001; 24(4):283-4. PubMed ID: 11565828
[No Abstract] [Full Text] [Related]
17. Cytotoxic T cells and immunotherapy.
Kitchingman GR; Rooney C
Pediatr Radiol; 1998 Jul; 28(7):489-91. PubMed ID: 9662564
[TBL] [Abstract][Full Text] [Related]
18. [Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes in EBV-related diseases].
Kuzushima K
Rinsho Ketsueki; 2000 Jun; 41(6):487-90. PubMed ID: 10921347
[No Abstract] [Full Text] [Related]
19. Immune-cell treatment of Epstein--Barr-virus-associated lymphoproliferative disorders.
Swinnen LJ
Best Pract Res Clin Haematol; 2006; 19(4):839-47. PubMed ID: 16997187
[TBL] [Abstract][Full Text] [Related]
20. Determining virological, serological and immunological parameters of EBV infection in the development of PTLD.
Davis JE; Sherritt MA; Bharadwaj M; Morrison LE; Elliott SL; Kear LM; Maddicks-Law J; Kotsimbos T; Gill D; Malouf M; Falk MC; Khanna R; Moss DJ
Int Immunol; 2004 Jul; 16(7):983-9. PubMed ID: 15159377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
